| Literature DB >> 29709256 |
Xavier Romero Ros1, Louis Vermeulen2.
Abstract
Novel immune therapeutic tools are rapidly expanding the anticancer arsenal. Despite this progress, patients with colorectal cancer (CRC) that spreads to vital parts of the body still have a dismal outcome. Transforming growth factor-β (TGF-β) plays a pivotal role in the development of CRC and metastasis. Important new work by Tauriello and colleagues has revealed that inhibition of TGF-β prevents tumor metastasis by enhancing a cytotoxic T cell response, suggesting that TGF-β inhibition is a promising pro-immunogenic therapy.Entities:
Keywords: CMS4; TGF-β; colorectal cancer; immunotherapy; mesenchymal subtype; metastasis
Mesh：
Substances：
Year: 2018 PMID： 29709256 DOI： 10.1016/j.trecan.2018.03.005
Source DB: PubMed Journal: Trends Cancer ISSN： 2405-8025